Clinical Trials Directory

Trials / Completed

CompletedNCT06350526

Radiological Characterization of Pulmonary Involvement in Patients With Hematological Diseases

Status
Completed
Phase
Study type
Observational
Enrollment
148 (actual)
Sponsor
New Valley University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hematologic malignancies are heterogeneous groups of neoplasia, with frequent pulmonary complications. These complications may be secondary to the patient's comorbidities, to the hemopathy itself, or its treatments. Divided into infectious and non-infectious complications, the etiologies are numerous and varied. This makes the diagnostic approach complex for the clinicians

Detailed description

Although infectious processes of the lungs are common in these immunosuppressed patient collectives, non-infectious causes account for up to half of the pulmonary manifestations found in hematologic malignancies. Besides the frequent infections including opportunistic pathogens, a broad differential diagnosis including drug-induced lung injury by cytostatic substances, cytokines, and innovative immunotherapeutic agents, rarer transfusion of blood products, and intrathoracic manifestations of the hematologic malignancy itself, must be kept in mind. Finally, vascular complications can also lead to pulmonary reactions. Early and consistent diagnostics and treatment of bronchopulmonary, intrathoracic, and vascular complications within the framework of hematologic systemic diseases can be essential for the patient's prognosis. Up to 25% of patients with profound neutropenia lasting for \>10 days develop lung infiltrates, which frequently do not respond to broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in most cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant Gram-negative pathogens, mycobacteria or respiratory viruses may be involved. In at-risk patients who have received trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis, filamentous fungal pathogens appear to be predominant, yet commonly not proven at the time of treatment initiation. In patients who do not improve rapidly with first-line therapy with broad spectrum antibiotics, cross-sectional thoracic CT imaging is essential. It provides much better definition of the pattern of radiological changes that includes three main groups: consolidation, nodules (micro- and macro-), and diffuse changes, as ground glass pattern. Discuss these radiological patterns and how this guides the appropriate initial investigations and treatment options will be of a great value to be followed.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTComplete Blood Countblood sample
DIAGNOSTIC_TESTC-reactive proteinserum sample
DIAGNOSTIC_TESTO2 saturationblood sample
DIAGNOSTIC_TESTSerum ferritin and D-dimerBlood sample
DIAGNOSTIC_TESTLiver and renal function testsBlood sample
DIAGNOSTIC_TESTLactate dehydrogenaseBlood sample
DIAGNOSTIC_TESTcoronavirus (SARS-CoV-2) swabThroat swab
RADIATIONCT chestRadiation

Timeline

Start date
2024-09-27
Primary completion
2025-08-01
Completion
2025-11-21
First posted
2024-04-05
Last updated
2025-11-24

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06350526. Inclusion in this directory is not an endorsement.